Gramer G, Garbade S F, Blau N, Lindner M
Centre for Paediatric and Adolescent Medicine, Department of General Paediatrics, Division of Metabolic Disorders, Heidelberg, Germany.
J Inherit Metab Dis. 2009 Feb;32(1):52-7. doi: 10.1007/s10545-008-0955-1. Epub 2008 Nov 21.
Tetrahydrobiopterin (BH(4)) loading has been performed for many years in patients detected by newborn screening for hyperphenylalaninaemia (HPA) to distinguish BH(4) cofactor synthesis or recycling defects from phenylalanine hydroxylase (PAH)-deficient HPA. Previous studies have shown that the pharmacokinetics of BH(4) shows high intra-individual and inter-individual variability.
Seventeen adult patients with PAH-deficient HPA were classified in one of three phenotypic groups (mild, moderate, classical PKU) according to their response to a standardized protein loading test. Genotype information was available for all participants. In a randomized controlled double-blind design, BH(4) loadings in single oral dosages of 10, 20 and 30 mg BH(4)/kg body weight (bw) were performed to assess BH(4) responsiveness. As part of this study, levels of BH(4) metabolites in dried blood spots were studied to provide information on the pharmacokinetics of BH(4) following oral administration.
Levels of biopterin and pterin (B + P) increased significantly with increasing BH(4) dose (p < 0.0001). Maximum B + P levels were reached 4 hours after application of BH(4). There was no significant difference in BH(4) pharmacokinetics between the three phenotypic groups of PKU. Male and female patients showed different levels of BH(4) metabolites following 10 mg BH(4)/kg bw, but not following 20 and 30 mg BH(4)/kg bw. There was no relationship between age of patients and BH(4) pharmacokinetics. There was no correlation between B + P levels and decrease in Phe level (p = 0.69).
BH(4) pharmacokinetics are variable between patients regarding absolute levels of BH(4) metabolites reached after BH(4) loading, but are similar regarding the interval to individual maximum B + P levels. Levels of B + P increase significantly with increasing BH(4) doses. There is no correlation between B + P levels and decrease in Phe level.
多年来,对于通过新生儿筛查发现的高苯丙氨酸血症(HPA)患者,一直采用四氢生物蝶呤(BH(4))负荷试验,以区分BH(4)辅因子合成或再循环缺陷与苯丙氨酸羟化酶(PAH)缺乏所致的HPA。既往研究表明,BH(4)的药代动力学显示出较高的个体内和个体间变异性。
17例PAH缺乏所致HPA的成年患者根据其对标准化蛋白质负荷试验的反应被分为三个表型组(轻度、中度、经典型苯丙酮尿症)之一。所有参与者均有基因型信息。采用随机对照双盲设计,给予单剂量口服10、20和30 mg BH(4)/kg体重(bw)的BH(4)负荷试验,以评估BH(4)反应性。作为本研究的一部分,研究了干血斑中BH(4)代谢产物的水平,以提供口服给药后BH(4)药代动力学的信息。
随着BH(4)剂量增加,生物蝶呤和蝶呤(B + P)水平显著升高(p < 0.0001)。应用BH(4)后4小时达到最大B + P水平。苯丙酮尿症三个表型组之间的BH(4)药代动力学无显著差异。男性和女性患者在给予10 mg BH(4)/kg bw后BH(4)代谢产物水平不同,但给予20和30 mg BH(4)/kg bw后无差异。患者年龄与BH(4)药代动力学之间无相关性。B + P水平与苯丙氨酸水平降低之间无相关性(p = 0.69)。
患者之间BH(4)药代动力学在BH(4)负荷后达到的BH(4)代谢产物绝对水平方面存在差异,但在达到个体最大B + P水平的时间间隔方面相似。B + P水平随BH(4)剂量增加而显著升高。B + P水平与苯丙氨酸水平降低之间无相关性。